Hantavirus Treatment: What Doctors Do (and What Doesn't Exist Yet)

When someone asks whether there is a cure for hantavirus, the honest answer is no — not in the sense of a drug that targets the virus and clears the infection. What medicine can do is keep the body alive long enough for the immune system to do the work itself. In hantavirus pulmonary syndrome (HPS), that window is narrow, and the difference between dying and surviving often comes down to how quickly a patient reaches an intensive-care unit and how skillfully the clinical team manages a cascade of rapidly shifting physiology.

1. Why there is no approved antiviral

Hantaviruses are negative-sense RNA viruses in the family Hantaviridae. Developing effective antiviral drugs against them is technically difficult for several reasons. First, the human immune response itself — particularly the cytokine storm triggered in the cardiopulmonary phase — accounts for a large share of the damage. Suppressing viral replication alone would not necessarily prevent the immunopathological cascade. Second, the patient population is small and geographically dispersed, which makes recruiting for randomized controlled trials expensive and slow. Third, animal models do not fully replicate human disease, complicating preclinical work.

The result is that, as of 2026, no antiviral drug has received regulatory approval in the United States, the European Union, or most other jurisdictions specifically for hantavirus infection.

2. Ribavirin: the drug that keeps being tried

Ribavirin is a broad-spectrum antiviral nucleoside analogue that has been administered to HPS patients since the 1990s, largely by analogy with its modest benefit in hantavirus hemorrhagic fever with renal syndrome (HFRS) caused by Old World strains such as Hantaan virus.

A randomized, double-blind, placebo-controlled trial conducted by the U.S. CDC and published in 2004 enrolled 242 patients with HFRS and found that intravenous ribavirin reduced mortality, peak creatinine, and the duration of oliguria. However, this trial covered Old World strains. For HPS caused by Sin Nombre and Andes viruses — the predominant strains in the Americas — the evidence is far weaker. Observational series have not shown a consistent mortality benefit, and a retrospective analysis of HPS cases in the American Southwest found no significant difference in outcomes between treated and untreated groups.

The working hypothesis is that ribavirin may be most useful when given very early in the febrile prodrome, before viraemia peaks and before the immunopathological phase begins. By the time a patient is in respiratory failure, viral replication has largely run its course and the harm driving the clinical picture is inflammatory rather than purely virological. Ribavirin at that stage offers little and carries its own toxicity profile — dose-dependent haemolytic anaemia, which compounds the haemodynamic instability already present.

Some South American centres continue to use ribavirin empirically in early confirmed or highly suspected cases, accepting its limitations. For the MV Hondius cluster, any ribavirin decisions are being made on a case-by-case basis in consultation with infectious disease specialists.

3. Supportive care: where survival actually happens

The backbone of HPS management is aggressive, protocol-driven supportive care in an ICU. The physiology the clinical team is fighting looks like this: capillary leak causes fluid to pour out of the vascular space into the lungs, cardiac output drops, oxygen delivery to tissues falls, and the patient can deteriorate from ambulatory to requiring mechanical ventilation in under six hours.

Fluid management

Fluid management in HPS is counterintuitive. Unlike sepsis from most bacterial causes — where aggressive fluid resuscitation is standard — HPS patients have leaky capillaries and are already moving fluid into the interstitium. Aggressive intravenous fluids can worsen pulmonary oedema and accelerate respiratory failure. Most experienced centres use a conservative fluid strategy, accepting a lower preload and relying on vasopressors rather than volume to maintain blood pressure.

Oxygen and mechanical ventilation

As oxygen saturation falls, supplemental oxygen is started early. When non-invasive support (high-flow nasal cannula, CPAP, BiPAP) is insufficient, the patient is intubated and placed on a mechanical ventilator. Lung-protective ventilation using low tidal volumes — typically 6 ml/kg of ideal body weight — with permissive hypercapnia reduces ventilator-induced lung injury and has become standard of care based on ARDS Network trial data extrapolated to HPS. Prone positioning is used in refractory hypoxaemia.

Vasopressors and inotropes

Most patients in the cardiopulmonary phase require vasopressor support to maintain mean arterial pressure above 65 mmHg. Noradrenaline is the first-line agent in most centres. When myocardial dysfunction is prominent — a finding seen in some severe HPS cases — inotropic support with dobutamine or milrinone may be added. Echocardiographic guidance helps distinguish between vasodilatory shock (typical ARDS picture) and cardiogenic shock (occasionally seen in HPS) because the treatment approaches differ.

4. ECMO: the last resort that saves lives

Extracorporeal membrane oxygenation (ECMO) is a form of life support in which blood is pumped outside the body, oxygenated through an artificial membrane, and returned to the circulation. It bypasses the lungs entirely and can sustain a patient who would otherwise die of refractory respiratory failure.

For HPS, ECMO has become a recognised rescue therapy at experienced centres. Case series from the United States, Canada, and Argentina have reported survival rates of 60–80% in carefully selected HPS patients placed on venovenous ECMO — meaningfully better than historical mortality of 30–40% for severe HPS overall. The selection criteria matter: patients who are cannulated while still haemodynamically responsive tend to do better than those cannulated in extremis.

The key limitation is access. ECMO requires specialised equipment, trained perfusionists, and experienced ICU teams. It is available at major academic medical centres and some regional hospitals, but not universally. Transfer to an ECMO-capable centre should be arranged early — before the patient deteriorates to a point where transport is no longer safe.

Venoarterial ECMO (which supports both the heart and lungs) has been used in HPS cases with severe myocardial depression alongside pulmonary failure, though the evidence base is thinner than for venovenous ECMO.

5. Convalescent plasma and other investigational approaches

During the MV Hondius outbreak and previous clusters, questions have arisen about whether convalescent plasma — serum drawn from survivors containing antibodies against the virus — could help newly infected patients. The rationale is straightforward, but the evidence is not strong. A small randomised trial of convalescent plasma in Andes virus HPS in Chile and Argentina produced inconclusive results, partly because enrolment was difficult and partly because timing of infusion relative to disease phase complicates interpretation.

Monoclonal antibodies targeting hantavirus surface glycoproteins are in early development. No candidate has reached Phase II trials for HPS as of 2026. Immunomodulatory strategies aimed at blunting the cytokine storm (analogous to approaches tested in COVID-19) are also being explored at the preclinical level but are not yet part of standard management.

6. How early presentation changes the odds

The single most actionable finding from HPS outcome data across multiple case series is that outcomes are substantially better when patients reach an ICU before full cardiopulmonary collapse. Patients who are admitted while still in the febrile prodromal phase — before oxygen levels have started to fall — have more time for the clinical team to prepare, more haemodynamic reserve for the interventions that follow, and are better candidates for ECMO if it is needed.

The implication for anyone who may have been exposed to hantavirus is unambiguous: do not wait. Fever plus any shortness of breath after possible exposure is a medical emergency. Tell the emergency department staff about the exposure at the start of the conversation. Hantavirus is not the first diagnosis most emergency physicians reach for when a patient presents with flu-like illness, and the clinical window in which intervention is most effective is narrow.

7. Prognosis factors

8. What to tell your doctor

If you are presenting to an emergency department with possible hantavirus exposure, be specific. The information that changes the clinical calculus is:

• Whether you were on the MV Hondius or in contact with a confirmed case, and the date
• Whether you have had any contact with rodent droppings, urine, or nests in the past eight weeks
• Whether you have been in an endemic region (Patagonia, rural Andes corridor, southwestern United States) and slept in rural accommodation
• Exact date of fever onset, so the clinical team can estimate what phase of disease you are in

This information helps the treating team triage your risk, order the right laboratory tests, and make the decision about ICU-level monitoring early rather than late.